Jiangsu Jinye Biopharmaceutical

Jiangsu Jinye Biopharmaceutical is a clinical-stage biotechnology company based in Nanjing, China, dedicated to the development of innovative peptide-based therapeutics for metabolic disorders. The company focuses on multi-target agonists, specifically targeting the GLP-1, GIP, and glucagon receptors to address unmet needs in obesity, type 2 diabetes, and NASH. Its lead candidate, JY09, is a triple receptor agonist currently undergoing clinical evaluation for weight management and glycemic control. By utilizing its proprietary peptide engineering platform, Jinye Biopharmaceutical aims to optimize the pharmacological properties of its candidates for superior clinical outcomes. The company is positioned within the competitive landscape of incretin-based therapies, leveraging local R&D expertise to develop next-generation treatments.